INSM:NGS-Insmed Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 68.57

Change

0.00 (0.00)%

Market Cap

USD 0.88B

Volume

1.82M

Analyst Target

USD 45.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Insmed Inc is a biopharmaceutical company. The Company is developing ARIKAYCE for inhalation (LAI), for patients with nontuberculous mycobacteria lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 126.52B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 69.68B
ARGX argenx NV ADR

N/A

USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 30.51B
ONC BeiGene, Ltd.

N/A

USD 26.35B
RPRX Royalty Pharma Plc

N/A

USD 19.31B
SMMT Summit Therapeutics PLC

N/A

USD 14.57B
INCY Incyte Corporation

N/A

USD 11.72B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 11.50B
MRNA Moderna Inc

N/A

USD 9.91B

ETFs Containing INSM

CURE:AU ETFS S&P Biotech ETF 2.65 % 0.00 %

N/A

USD 0.04B
ISCG iShares Morningstar Small.. 0.57 % 0.00 %

N/A

USD 0.61B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.56 % 0.00 %

N/A

USD 1.80B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.56 % 0.00 %

N/A

USD 1.80B
RSSL Global X Funds 0.55 % 0.00 %

N/A

USD 1.46B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.54 % 0.00 %

N/A

USD 4.13B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.54 % 0.00 %

N/A

USD 4.13B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.54 % 0.00 %

N/A

USD 2.91B
R2US:SW SPDR® Russell 2000 US Sm.. 0.54 % 0.00 %

N/A

USD 4.18B
XRS2:SW Xtrackers Russell 2000 UC.. 0.54 % 0.00 %

N/A

USD 1.82B
ITWO Proshares Russell 2000 Hi.. 0.47 % 0.00 %

N/A

USD 0.04B
VISM:AU Vanguard MSCI Internation.. 0.18 % 0.00 %

N/A

USD 0.29B
HDG ProShares Hedge Replicati.. 0.00 % 0.95 %

N/A

USD 0.02B
IWM iShares Russell 2000 ETF 0.00 % 0.19 %

N/A

N/A
JKJ 0.00 % 0.25 %

N/A

N/A
JKK 0.00 % 0.30 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

N/A

USD 0.66B
BTEC 0.00 % 0.42 %

N/A

N/A
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.00 %

N/A

USD 1.19B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.00 %

N/A

USD 10.02B
URTY ProShares UltraPro Russel.. 0.00 % 0.95 %

N/A

USD 0.33B
UWM ProShares Ultra Russell20.. 0.00 % 0.95 %

N/A

USD 0.32B
VTWG Vanguard Russell 2000 Gro.. 0.00 % 0.20 %

N/A

USD 0.94B
VTWO Vanguard Russell 2000 Ind.. 0.00 % 0.15 %

N/A

USD 11.00B
R2US:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 4.74B
XRS2:F Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

N/A

USD 1.19B
XRS2:XETRA Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

N/A

N/A
ZPRR:XETRA SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

N/A

N/A
ISCB iShares Morningstar Small.. 0.00 % 0.00 %

N/A

USD 0.19B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.68% 82% B 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.68% 82% B 74% C
Trailing 12 Months  
Capital Gain 151.63% 97% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 151.63% 97% N/A 97% N/A
Trailing 5 Years  
Capital Gain 277.80% 94% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 277.80% 94% A 92% A
Average Annual (5 Year Horizon)  
Capital Gain 398.30% 92% A 97% N/A
Dividend Return 398.30% 92% A 97% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 2,018.86% 9% A- 3% F
Risk Adjusted Return 19.73% 79% B- 54% F
Market Capitalization 0.88B 99% N/A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 46.51 5% 3%
Price / Cash Flow Ratio -18.31 91% 89%
Price/Free Cash Flow Ratio -6.05 83% 87%
Management Effectiveness  
Return on Equity -890.75% 9% 4%
Return on Invested Capital -79.74% 36% 15%
Return on Assets -29.31% 55% 18%
Debt to Equity Ratio 386.64% 6% 6%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector